Repligen (RGEN) Beats On Q3 Earnings, Lifts 2019 Guidance
Zacks Investment Research | Nov 01, 2019 02:49AM ET
Repligen Corporation (NASDAQ:RGEN) reported third-quarter 2019 earnings per share of 26 cents, beating the Zacks Consensus Estimate of 20 cents. The figure also surpassed the year-ago earnings of 20 cents.
Also, the company’s total revenues of $69.4 million surpassed the Zacks Consensus Estimate of $66 million. Additionally, the top line surged 40% year over year (42% at constant currency) on strong performance by the filtration and chromatography product franchises.
We remind investors that in May 2019, Repligen closed the previously announced buyout of the privately held bioprocess analytics company C Technologies for a $240-million cash-and-stock deal. Excluding the impact of currency and acquisitions/divestures, Repligen’s revenues grew 28% organically year over year.
Repligen earns revenues from the sale of several products, which can be categorized under three segments, namely Filtration, Chromatography and Protein products.
Shares of Repligen were up 3.1% on Thursday, probably on the back of encouraging earnings results and updated sales guidance issued by the company. In fact, the stock has soared 50.7% so far this year against the industry’s decline of 0.9%.
Quarter in Detail
In the reported quarter, adjusted research and development expenses were $5.1 million, up 41.7% from the year-ago figure.
Adjusted selling, general and administrative expenses were $18.7 million, reflecting an increase of 48.4% year over year.
As of Sep 30, 2019, Repligen had cash and cash equivalents of $513.5 million compared with $ 208.9 million at the end of Jun 30, 2019.
2019 Guidance
Repligen raised its previously issued annual forecast for revenues and earnings.
The company expects sales in the range of $267-$270 million, implying organic growth of 31-32%. Previously, revenues were expected in the range of $ 264-$268 million, indicating organic revenue growth of 29-31%.
C Technologies is expected to add $16-$17 million to Repligen’s revenues in about seven months of ownership in 2019.
Adjusted net income is projected in the range of $50-$52 million, lifted from the previous guidance of $47-$49 million. Adjusted income from operations is anticipated in the band of $62-$64 million, upped from $60-$62 million expected previously.
Adjusted EPS is envisioned in the range of $1-$1.04, raised from the previous view of 94-98 cents.
Get The News You Want
Repligen Corporation Price, Consensus and EPS Surprise
Zacks Rank & Stocks to Consider
Repligen currently carries a Zacks Rank #3 (Hold). Better-ranked stocks from the healthcare sector include Anika Therapeutics Inc. (NASDAQ:ANIK) , Acorda Therapeutics, Inc. (NASDAQ:ACOR) and BeiGene, Ltd. (NASDAQ:BGNE) , all sporting a Zacks Rank #1 (Strong Buy). You can see .
Anika’s earnings estimates have been revised 16% upward for 2019 and 19.1% for 2020 over the past 60 days. The stock has skyrocketed 109.4% year to date.
Acorda’s loss per share estimates have been narrowed 20.4% for 2019 and 43% for 2020 over the past 60 days.
BeiGene’s loss per share estimates have been narrowed 2.2% for 2019 and 0.3% for 2020 over the past 60 days.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.5% per year. So be sure to give these hand-picked 7 your immediate attention.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.